# Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects

> **NCT05576454** · PHASE1 · COMPLETED · sponsor: **Bio-Thera Solutions** · enrollment: 207 (actual)

## Conditions studied

- Severe Asthma

## Interventions

- **DRUG:** Mepolizumab Injection (BAT2606 Injection)
- **DRUG:** Mepolizumab Injection (EU-licensed Nucala)
- **DRUG:** Mepolizumab Injection (US-licensed Nucala)

## Key facts

- **NCT ID:** NCT05576454
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-20
- **Primary completion:** 2023-05-26
- **Final completion:** 2023-06-19
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2023-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576454, "Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05576454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*